Impilo launches Immedica – a platform for pan-European niche specialty pharma launch, commercialization and distribution services

Impilo has launched Immedica Pharma – a pan-European specialty pharma commercialization and distribution platform. Immedica’s plan is to quickly establish a fast-growing EUR 100m+ leading pan-European niche specialty pharma portfolio composed of partner products as well as proprietary products rights – and spanning from pre-approval stage through peak sales. This will be achieved through world-class launch, commercialization, and distribution capabilities lead by a management team with a very strong and established track record within niche specialty pharma. 

Immedica was formed through the combination of an existing platform, recruitment of new management and key employees. Immedica will be built on the initial acquisition of Medical Need Europe – a rapidly growing, Northern Europe focused, launch- and commercial distribution partner for rare disease therapies and orphan drugs. With a portfolio of 15 drugs and an organic growth trajectory of over 30% per year, Medical Need Europe is a formidable starting point for a significant expansion across a pan-European and Middle East territory. Medical Need Europe’s employees will continue in their current roles and the company’s CEO and co-founder Peder Walberg will remain committed to the business, both as a shareholder and as an operative board member with specific focus on business development and partner relations at Immedica.

In addition, Immedica is delighted to have recruited Anders Edvell as CEO for Immedica and Carl Belmadani as Head of Commercial Operations. Mr. Edvell, most recently serving as CEO for Unimedic and prior to that as Head of SOBI Partner Products – and Mr. Belmadani, most recently Head of Commercial Operations at SOBI Partner Products, both hold unmatched track records and experience from this niche business model and sector and will be instrumental in realizing Immedica’s ambitions. Immedica is looking to add several additional key positions across Europe in the short term as a consequence of its significant scale up of activities.

Just recently, a significant addition to the portfolio was signed with the Spanish pharma company PharmaMar, under which Immedica becomes the exclusive distributor for their innovative anti-cancer drug Yondelis® in the Nordics and the Central and Eastern European territories. Yondelis is an established treatment for patients suffering from soft tissue sarcomas (STS) and platinum sensitive ovarian cancer.

“I believe Immedica will fill an important role in the European pharma environment as a facilitator making new niche specialty medicines available for patients with rare diseases”, says Anders Edvell, CEO of Immedica. “Our ambition is to leverage our experience and capabilities in providing market and patient access for new niche therapies. By providing these services combined with an understanding of the commercialization requirements for niche pharmaceuticals in a broader EU and Middle East territory, we believe Immedica will become the preferred partner for many innovative small biotechs with the ambition to make their medicines commercially available in Europe and the Middle East.” 

”We are highly impressed with what Medical Need has achieved during its short history and pleased that its founder Peder Walberg will continue to serve its partners and remain invested in the business. Taken together with Mr Edvell’s and Mr Belmadani’s outstanding track records and relationships, we have the foundation to establish the leading pan European launch and distribution partner for niche specialty drug originators, as evidenced by the significant new partnership established with PharmaMar” says Magnus Edlund, partner at Impilo. 

Impilo, which was established in 2017, has more than SEK 3.5 bn in capital from leading Nordic and international investors. 

For more information:

Magnus Edlund, Impilo, Partner
magnus.edlund@impilo.se 
+46 761 15 10 61

Fredrik Strömholm, Impilo, Partner, and Chairman of Immedica
fredrik.stromholm@impilo.se
+46 761 15 10 65

Anders Edvell, Immedica, CEO
anders.edvell@immedica.com
+46 705 44 61 26

 _____________________________________________________

Impilo is an investment company focused on investments in Nordic healthcare companies active in the pharmaceutical, medical devices, care services and other health related areas. Impilo’s perspective is that the portfolio companies must contribute to a positive development in their field and thus society in order to be successful longer term. 

Tags:

About Us

We are an investment company with an approach based on the premise that we must invest and drive development so as to produce a lasting, positive effect on the future of our investee companies, society at large and ourselves. A premise that also benefits our investment success, since it forces us to understand each business and reduce risks, and thereby develop our ability to act as progressive owners. We invest in people’s opportunities to enjoy healthier lives in the future.

Subscribe